|
KMID : 1011920120130020023
|
|
International Journal of Arrhythmia
2012 Volume.13 No. 2 p.23 ~ p.27
|
|
|
New antiarrhythmia drugs
|
|
Park Hyung-Wook
|
|
|
Abstract
|
|
|
|
Antiarrhythmia drugs are designed to maintain sinus rhythm, prevent arrhythmia, and modulate ion channel function. Several classification of these drugs have been developed, mostly according to the targeted protein. One drug developmental strategy is to find tissue-specific ion channel blockers that are devoid of proarrhythmogenic risks. Treating ventricular arrhythmia is problematic, despite the development of implantable cardioverter-defibrillators. The currently available pharmacologic agents have limited efficacy and/or carry a risk of side effects. A major obstacle in the development of novel antiarrhythmia drugs is related to the complexity of electrical signaling, which in turn introduces safety concerns. Classic antiarrhythmia drugs are of limited effectiveness and post the risk of lifethreatening ventricular tachycardia/ventricular fibrillation. Very few antiarrhythmia drugs have been successful in the last few decades due to safety concerns or limited benefits in comparison with those of existing therapies. New antiarrhythmia drugs, such as atrial-specific and/or multichannel blockers, upstream therapy, and anti-remodeling drugs, are emerging. The different mechanisms of action of antiarrhythmia drugs may increase the therapeutic options available for the safe treatment of arrhythmia in a wide variety of pathophysiological situations.
|
|
|
KEYWORD
|
|
|
antiarrhythmia drug, ion channel
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|